BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 28225768)

  • 1. Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Deyab G; Hokstad I; Whist JE; Småstuen MC; Agewall S; Lyberg T; Bottazzi B; Meroni PL; Leone R; Hjeltnes G; Hollan I
    PLoS One; 2017; 12(2):e0169830. PubMed ID: 28225768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of anti-rheumatic treatment on selenium levels in inflammatory arthritis.
    Deyab G; Hokstad I; Aaseth J; Småstuen MC; Whist JE; Agewall S; Lyberg T; Tveiten D; Hjeltnes G; Zibara K; Hollan I
    J Trace Elem Med Biol; 2018 Sep; 49():91-97. PubMed ID: 29895378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.
    Deyab G; Hokstad I; Whist JE; Smastuen MC; Agewall S; Lyberg T; Ronda N; Mikkelsen K; Hjeltnes G; Hollan I
    Arthritis Res Ther; 2017 Oct; 19(1):232. PubMed ID: 29041979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Furst DE; Kay J; Wasko MC; Keystone E; Kavanaugh A; Deodhar A; Murphy FT; Magnus JH; Hsia EC; Hsu B; Xu S; Rahman MU; Doyle MK
    Rheumatology (Oxford); 2013 Oct; 52(10):1845-55. PubMed ID: 23838027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease.
    Hollan I; Bottazzi B; Cuccovillo I; Førre ØT; Mikkelsen K; Saatvedt K; Almdahl SM; Mantovani A; Meroni PL;
    Arthritis Care Res (Hoboken); 2010 Mar; 62(3):378-85. PubMed ID: 20391484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors.
    Hjeltnes G; Hollan I; Førre Ø; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    J Rheumatol; 2012 Jul; 39(7):1341-7. PubMed ID: 22660798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
    Hull DN; Williams RO; Pathan E; Alzabin S; Abraham S; Taylor PC
    Clin Exp Immunol; 2015 Sep; 181(3):401-6. PubMed ID: 25766640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
    Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
    Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum pentraxin 3 levels are negatively associated with carotid intima media thickness in non-obese rheumatoid arthritis patients.
    Kahlow BS; Petisco R; Skare TL; Goeldner I; Nisihara RM; Messias-Reason IJ
    Int J Cardiol; 2016 Oct; 221():298-301. PubMed ID: 27404695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of pentraxin 3 in patients with spondyloarthritis.
    Nisihara R; Skare TL; Zeni JO; Rasera H; Lidani K; Messias-Reason I
    Biomarkers; 2018 Feb; 23(1):14-17. PubMed ID: 28043168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].
    Manger B; Michels H; Nüsslein HG; Schneider M; Sieper J;
    Z Rheumatol; 2007 Feb; 66(1):72-5. PubMed ID: 17221253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis.
    Nguyen THP; Fagerland MW; Deyab G; Hjeltnes G; Hollan I; Feinberg MW; Eilertsen GØ; Mikkelsen K; Agewall S
    PLoS One; 2021; 16(6):e0253793. PubMed ID: 34170978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment.
    Happonen KE; Saxne T; Geborek P; Andersson M; Bengtsson AA; Hesselstrand R; Heinegård D; Blom AM
    Arthritis Res Ther; 2012 Jan; 14(1):R15. PubMed ID: 22264230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.